TAS-102
- Generic Name
- TAS-102
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 733030-01-8
- Unique Ingredient Identifier
- -
- Background
TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer. It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine. Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trif...
- Indication
用于治疗曾经接受氟嘧啶，奥沙利铂和伊立替康为基础的化疗，抗VEGF生物治疗和抗EGFR治疗（如果是RAS野生型）无效的转移性结直肠癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT04104139
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Conditions
- Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT04097028
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 20
- Registration Number
- NCT04074343
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
🇺🇸UC Davis Comprehensive Cancer Center, Sacramento, California, United States
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
- Conditions
- Stage III Intrahepatic Bile Duct Cancer AJCC v8Stage IIIA Distal Bile Duct Cancer AJCC v8Stage IIIB Distal Bile Duct Cancer AJCC v8Advanced Bile Duct CarcinomaStage IIIB Intrahepatic Bile Duct Cancer AJCC v8Stage III Gallbladder Cancer AJCC v8Stage IIIA Gallbladder Cancer AJCC v8Advanced Gallbladder CarcinomaRefractory Gallbladder CarcinomaStage IIIA Intrahepatic Bile Duct Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 28
- Registration Number
- NCT04072445
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
- Conditions
- Metastatic Colorectal CarcinomaStage III Rectal Cancer AJCC v8Stage IIIB Colon Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIB Rectal Cancer AJCC v8Stage IIIC Colon Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IVA Colon Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage IV Rectal Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 12
- Registration Number
- NCT03992456
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 102
- Registration Number
- NCT03981614
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT03974594
- Locations
- 🇨🇳
Tangdu Hospital,Fourth Military Medical University, Xi'an, Shanxi, China
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
- Conditions
- Refractory Colorectal CarcinomaStage IIIC Colorectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT03844620
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Sym004 Versus TAS-102 in Patients With mCRC
- Conditions
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Symphogen A/S
- Registration Number
- NCT03717038
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
- Conditions
- Interventions
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Emory University
- Target Recruit Count
- 64
- Registration Number
- NCT03368963
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.